. Author manuscript; available in PMC: 2021 Aug 1.

Published in final edited form as: Am J Ophthalmol. 2020 Apr 10;216:132–139. doi: 10.1016/j.ajo.2020.04.006

TABLE.

Clinical Characteristics of Patients with Limbal Stem Cell Deficiency and Normal Controls

	Control group	LSCD group				P^*	Subgroup comparison P<0.05
	Control group	All	Stage I	Stage II	Stage III	P^*	Subgroup comparison P<0.05
Eyes (%)	52	69	27(39.7)	27(39.7)	14(20.6)
BCVA logMAR	0.0±0.0	1.1±0.7	0.6±0.9	1.4±1.3	1.6±1.0	<0.001	1, 2, 3, 4, 5
Clinical Score	0±0	5.35±2.76	2.4±1.1	6.3±1.1	9.0±1.0	<0.001	1, 2, 3, 4, 5, 6
OCT-CET3 (μm)	55.0±3.0	41.6±10.8	49.5±2.9	38.9±9.6	32.8±12.2	<0.001	1,2, 3, 4, 5, 6
mLET (μm)
Superior	108.4±23.8	68.0±21.7	72.8±19.9	64.3±24.3	65.8±19.5	<0.001	1, 2, 3
Inferior	102.0±27.0	71.8±21.4	71.3±16.5	75.3±26.3	66.0±19.0	<0.001	1, 2, 3
Nasal	86.7±14.6	69.0±17.5	72.9±19.3	70.6±16.5	58.4±11.4	<0.001	1, 2, 3, 5, 6
Temporal	84.6±14.1	70.3±17.4	78.0±15.9	66.3±16.7	63.1±16.9	<0.001	2, 3, 4, 5

P values of ANOVA performed among the control group and LSCD groups; In subgroup comparison, 1. Control vs. Stage I; 2. Control vs. Stage II; 3. Control vs. Stage III; 4. Stage I vs. Stage II; 5. Stage I vs. Stage III; 6. Stage II vs. Stage III.